Streptomycin Committee, Central Office, Veterans Administration. The effect of streptomycin upon pulmonary tuberculosis. Preliminary report of a cooperative study of 223 patients by the Army, Navy, and Veterans Administration. Am Rev Tuberc1947;56:485–507.
2.
United States Public Health Service Cooperative Investigation of Antimicrobial Therapy of Tuberculosis: V: Report on thirty-two week observation on combinations of isoniazid, streptomycin, and para-amino salicylic acid. Am Rev Tuberc1954;70:521–6.
3.
FerebeeSH. Controlled chemoprophylaxis trials in tuberculosis. A general review. Adv Tuberc Res1970;17:28–106.
4.
CombsDLO'BrienRJGeiterLJ. USPHS Tuberculosis Short-Course Chemotherapy Trial 21: Effectiveness, toxicity, and acceptability. The report of final results. Ann Intern Med1990;112:397–406.
5.
WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Anti-tuberculosis drug resistance in the world. WHO Global Tuberculosis Programme, 1997. WHO/TB/97.229.
6.
BurmanWJCohnDLRietmeijerCAJudsonFNSbarbaroJARevesRR. Noncompliance with directly observed therapy for tuberculosis. Epidemiology and effect on the outcome of treatment. Chest1997;111:1168–73.
7.
VernonAABurmanWBenatorDKhanABozemanL. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Lancet1999;353:1843–7.
8.
The USPHS Rifapentine Trial Group, VernonAVillarinoEGeiterLO'BrienR. Design of US Public Health Service (USPHS) Study 22: a trial of once weekly isoniazid (INH) and rifapentine (Rpt) in the continuation phase of TB treatment. Presented at the 1997 American Thoracic Society International Conference; 1997 May; San Francisco (CA).
9.
Centers for Disease Control and Prevention, National Center for HIV, STD, and TB Prevention. Guidelines for data safety and monitoring boards. Atlanta (GA): NCHSTP; 1996.
10.
MarshallJG. Using evaluation research methods to improve quality. Health Libr Rev1995;12:159–72.
11.
BlancDiana Chang. Incentives and disincentives for new anti-tuberculosis drug development—situational analysis. Position paper for STOP TB Initiative, World Health Organization. Presented at the Global Tuberculosis Research Initiative, Second Meeting; 1999 June 29—July 1; Casablanca, Morocco. Pharmacoeconomics report available from: URL: http://www.tballiance.org
12.
DennettSBellLDombeckMSamadiH. Estimating the cost of conducting clinical trials for approval of a new anti-tuberculosis agent. Chapter 3. [In draft, for a monograph on the pharmaco-economics of TB drug development. Available at: URL: http://tbt2.rti.org/tbpharmacoec/report.cfm] Supported by the Global Alliance on TB Drug Development.
